Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL27531913 | 1.00 | ALDH1A1 (0.33) | ALDH1A1TSHRHSD17B10LMNA | |
| Lithium Ion SCHEMBL74921 | 1.00 | — | — | |
| Lithium Ion SCHEMBL5676964 | 0.94 | ALDH1A1 (0.30) | ALDH1A1TSHRHSD17B10 | |
| Lithium Ion SCHEMBL4664489 | 0.94 | ALDH1A1 (0.30) | ALDH1A1TSHRHSD17B10 | |
| Lithium Ion SCHEMBL28092084 | 0.88 | — | — | |
| SCHEMBL216766 | 0.86 | ALDH1A1 (0.33) | ALDH1A1TSHRHSD17B10LMNA | |
| SCHEMBL1549779 | 0.86 | ALDH1A1 (0.33) | ALDH1A1TSHRHSD17B10LMNA | |
| SCHEMBL3356662 | 0.86 | TSHR (0.33) | ALDH1A1TSHRHSD17B10LMNA | |
| SCHEMBL6755016 | 0.86 | ALDH1A1 (0.33) | ALDH1A1TSHRHSD17B10LMNA | |
| SCHEMBL6751743 | 0.86 | ALDH1A1 (0.33) | ALDH1A1TSHRHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115698137-A | Process for preparing multifunctional organosiloxanes and compositions comprising the same | 美国陶氏有机硅公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-107001622-B | Novel polymers containing grafted sodium or lithium bis (sulfonyl) imide salts, method for the production thereof and use thereof as battery electrolytes | CDP创新公司 | 2020-01-07 | — | — | CN | disclosed |
| EP-2175320-B1 | ALKALI-DEVELOPABLE PHOTOSENSITIVE RESIN COMPOSITION | ADEKA CORP (JP) | 2013-03-13 | — | — | EP | disclosed |
| US-8338081-B2 | Alkali-developable photosensitive resin composition and β-diketone compound | ADEKA CORPORATION (JP) | 2012-12-25 | — | — | US | disclosed |
| EP-1544187-B1 | 1,7,8-TRIFLUORONAPHTHALENE-2-NAPHTHOL, AND METHODS FOR PRODUCING LIQUID CRYSTAL COMPOUNDS USING SAME | DAINIPPON INK & CHEMICALS (JP) | 2011-02-16 | — | — | EP | disclosed |
| US-20100129753-A1 | ALKALI-DEVELOPABLE PHOTOSENSITIVE RESIN COMPOSITION AND BETA-DIKETONE COMPOUND | ADEKA CORPORATION (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-2175320-A1 | ALKALI-DEVELOPABLE PHOTOSENSITIVE RESIN COMPOSITION AND -DIKETONE COMPOUND | Adeka Corporation (JP) | 2010-04-14 | — | — | EP | disclosed |
| US-7384934-B2 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-7214835-B2 | 1,7,8-Trifluoronaphthalene-2-naphthol, and method for producing liquid crystal compound using same | DAINIPPON INK & CHEMICALS, INC. (JP) | 2007-05-08 | — | — | US | disclosed |
| EP-1546134-B1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES | LILLY CO ELI (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060270656-A1 | Substituted piperazines of azepines, oxazepines and thiazepines | ELI LILLY AND COMPANY | 2006-11-30 | — | — | US | disclosed |
| US-20060163537-A1 | 1,7,8-Trifluoronaphthalene-2-naphthol, and method for producing liquid crystal compound using same | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1664063-A1 | SUBSTITUTED PIPERAZINES OF AZEPINES, OXAZEPINES, AND THIAZEPINES | ELI LILLY AND COMPANY (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20060084643-A1 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY | 2006-04-20 | — | — | US | disclosed |
| EP-1546134-A1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES | ELI LILLY AND COMPANY (US) | 2005-06-29 | — | — | EP | disclosed |
| EP-1544187-A1 | 1,7,8-TRIFLUORONAPHTHALENE-2-NAPHTHOL, AND METHOD FOR PRODUCING LIQUID CRYSTAL COMPOUND USING SAME | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2005-06-22 | — | — | EP | disclosed |
| WO-2005026177-A1 | SUBSTITUTED PIPERAZINES OF AZEPINES, OXAZEPINES, AND THIAZEPINES | ELI LILLY AND COMPANY (US) | 2005-03-24 | — | — | WO | disclosed |
| WO-2004014895-A1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES | ELI LILLY AND COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270656-A1 | Substituted piperazines of azepines, oxazepines and thiazepines | HRH4, HRH2, HRH3 | ALDH1A1 2523/4885TSHR 173/4885HSD17B10 1800/4885 |
| US-20060163537-A1 | 1,7,8-Trifluoronaphthalene-2-naphthol, and method for producing liquid crystal compound using same | NOC2L, SNX2, NEFM | ALDH1A1 1484/4885TSHR 3402/4885HSD17B10 1034/4885 |
| US-20100129753-A1 | ALKALI-DEVELOPABLE PHOTOSENSITIVE RESIN COMPOSITION AND BETA-DIKETONE COMPOUND | RPS14, ACAD11, OR10J3 | ALDH1A1 1770/4885TSHR 3404/4885HSD17B10 278/4885 |
| US-20060084643-A1 | Piperazine substituted aryl benzodiazepines | GABBR1, GABBR2, GABRA5 | ALDH1A1 215/4885TSHR 62/4885HSD17B10 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.